NGL Fine Chem Ltd

₹ 1,658 -2.35%
02 Dec - close price
About

Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]

Key Points

Product Portfolio
Presently, Veterinary APIs is the main product of the company which account for 88% of its revenues, followed by Veterinary Formulations (5%), Human APIs (4%), & Others (3%). [1]
24 APIs (22 veterinary, 2 human), 4 intermediates, 10 finished dosage forms
Leadership in top 5 products – 50%+ market share. [2]

  • Market Cap 1,025 Cr.
  • Current Price 1,658
  • High / Low 2,935 / 1,377
  • Stock P/E 46.6
  • Book Value 335
  • Dividend Yield 0.11 %
  • ROCE 33.9 %
  • ROE 27.9 %
  • Face Value 5.00

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.0%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
37.21 37.42 35.44 42.31 68.34 72.72 71.77 75.86 78.37 81.14 84.06 64.61 67.72
32.90 34.19 33.15 28.89 47.94 50.32 50.98 52.29 61.21 68.64 73.50 63.10 58.57
Operating Profit 4.31 3.23 2.29 13.42 20.40 22.40 20.79 23.57 17.16 12.50 10.56 1.51 9.15
OPM % 11.58% 8.63% 6.46% 31.72% 29.85% 30.80% 28.97% 31.07% 21.90% 15.41% 12.56% 2.34% 13.51%
0.98 1.19 0.83 2.19 2.76 3.51 2.30 4.55 4.39 3.84 2.98 3.14 0.47
Interest 0.58 0.64 0.60 0.60 0.54 0.37 0.33 0.37 0.40 0.42 1.54 0.50 0.12
Depreciation 1.97 2.07 2.21 2.10 2.05 2.11 2.08 2.18 2.20 2.42 3.48 3.60 3.25
Profit before tax 2.74 1.71 0.31 12.91 20.57 23.43 20.68 25.57 18.95 13.50 8.52 0.55 6.25
Tax % 14.23% 34.50% 164.52% 27.42% 23.19% 24.41% 33.08% 25.22% 26.65% 26.30% 19.60% 5.45% 25.44%
Net Profit 2.35 1.13 -0.20 9.37 15.81 17.71 13.84 19.13 13.91 9.95 6.87 0.52 4.67
EPS in Rs 3.80 1.83 -0.32 15.17 25.59 28.67 22.40 30.96 22.52 16.11 11.12 0.84 7.56
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
153 152 258 318 298
121 130 178 249 264
Operating Profit 32 22 80 68 34
OPM % 21% 14% 31% 21% 11%
4 1 8 11 10
Interest 3 3 2 2 3
Depreciation 6 8 8 10 13
Profit before tax 28 12 78 67 29
Tax % 27% 31% 27% 25%
Net Profit 20 8 57 50 22
EPS in Rs 32.58 13.50 91.81 80.77 35.63
Dividend Payout % 5% 13% 2% 2%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 28%
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 35%
TTM: -66%
Stock Price CAGR
10 Years: 61%
5 Years: 34%
3 Years: 59%
1 Year: -37%
Return on Equity
10 Years: %
5 Years: %
3 Years: 29%
Last Year: 28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
3 3 3 3 3
Reserves 89 96 151 200 204
27 28 16 30 27
23 26 36 44 40
Total Liabilities 142 154 207 277 274
61 68 64 89 89
CWIP 0 0 12 6 16
Investments 9 11 29 29 33
73 75 102 153 137
Total Assets 142 154 207 277 274

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022
9 20 27 14
-10 -20 -25 -14
0 -1 -1 -1
Net Cash Flow -1 -0 2 -1

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 79 63 53 74
Inventory Days 106 155 132 137
Days Payable 92 116 103 91
Cash Conversion Cycle 93 102 82 120
Working Capital Days 107 93 76 117
ROCE % 14% 54% 34%

Shareholding Pattern

Numbers in percentages

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
73.83 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.05 0.05
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
26.16 26.19 26.19 26.19 26.19 26.19 26.19 26.19 26.19 26.18 26.14 26.13

* The XBRL reporting format changed from Sep'2022 onwards. The new format added details about banks and foreign portfolio investors. These were not available earlier.
The sudden increase in FII or DII might be because of these changes.

Please click on the line-items to see the names of individual entities.

Documents

Concalls